Inaphaea is pleased to announce the execution of an exclusive licence agreement with UK-based Dominion Biotech Ltd for Inaphaea’s PredictRx® platform. PredictRx is a personalised cancer screening service whereby a patient’s tumour sample is processed into Patient Derived Cells (PDCs) and subjected to a comprehensive drug combination screening panel to determine optimal chemotherapy treatment protocols.
A collaborative approach
Under the terms of the Agreement, Inaphaea will receive a 50% share of global net revenues from the PredictRx® service to be offered by Dominion. Dominion and Inaphaea will also share ownership of any new Patient Derived Cells (PDCs) developed.
The Agreement is for a period of 2 years with annual renewal thereafter. Either party may initiate a buyout of the rights of the other party after an initial period of 18 months under pre-agreed terms based on a multiple of trailing net revenue. Although initial revenues under the Agreement are expected to be modest, the arrangement is strategically important in demonstrating the commercial application of ValiRx’s platform and establishing future buyout value.
Mark Eccleston, CEO of ValiRx commented: “We have expanded our relationship with Dominion as we continue to develop and commercialise Inaphaea’s asset base. PredictRx is a pioneering, in-vitro approach for predicting drug sensitivity for cancer therapies at the individual patient level based on analysis of the patient’s own cancer cells. This can deliver significant benefit by identifying the most effective treatment options leading to a truly personalised approach to therapy which ultimately
should deliver improved outcomes for patients. Inaphaea’s focus is translational drug development services and monetising of its biobank through its PDC models and through this license to Dominion which will develop and commercialise the PredictRx clinical service globally.”
Anthony Holmes, CEO of Dominion added: “We’re delighted to expand our successful partnership with Inaphaea by bringing the PredictRx platform to market globally. This innovative personalised cancer screening service represents a significant advancement in precision oncology – using a patient’s own cancer cells to identify the most effective treatment options before therapy begins. By leveraging our established network of oncologists and patient-derived cell expertise, we can now offer clinicians and patients a powerful tool to optimise treatment decisions from day one. This licensing agreement demonstrates our commitment to translating cutting-edge science into real-world clinical benefits that can improve patient outcomes and potentially reduce the trial-and-error approach that too often characterises cancer treatment today.”
To find out more about Inaphaea’s range of services, click here.